Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2012 (2012), Article ID 508683, 10 pages
Research Article

The Evaluation of Chinese Therapeutic Food for the Treatment of Moderate Dyslipidemia

1School of Biomedical and Health Sciences, Victoria University, P.O. Box. 14428, Melbourne, VIC 8001, Australia
2School of Engineering and Science, Victoria University, P.O. Box 14428, Melbourne, VIC 8001, Australia

Received 17 August 2011; Accepted 30 December 2011

Academic Editor: Myeong Soo Lee

Copyright © 2012 Shu Sun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The clinical efficacy of the Chinese therapeutic food (specifically hawthorn fruit and Chinese kiwifruit-extract compound) on dyslipidemia was evaluated in this placebo-controlled, double blind, paired clinical trial conducted in Melbourne, Australia. Forty-three participants diagnosed with moderate dyslipidemia and met the study criteria were randomly assigned to Group A or B, with baseline characteristics matched. Twenty-seven participants completed all the tests, the blood lipid profile including total cholesterol (TC), high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c), and triglycerides (TG) was analysed. The traditional Chinese medicine diagnosis was made based on participants’ symptoms and signs. The results indicate that a four-week intake of the compound increased the serum HDL-c levels by 5% ( 𝑃 = 0 . 0 2 6 ) and decreased the ratios of TC/HDL-c and LDL-c/HDL-c ( 𝑃 = 0 . 0 1 2 and 𝑃 = 0 . 0 4 4 , resp.). The placebo intake did not significantly change the blood lipid profile. In the initial 43 participants with dyslipidemia, 76.7% of them were diagnosed with “Spleen deficiency” and 58.1% with “Liver qi stagnation.” The intake of hawthorn fruit and Chinese kiwifruit extract compound may increase the serum levels of HDL-c and decrease the ratios of TC/HDL-c and LDL-c/HDL-c, therefore, may reduce the risk of cardiovascular disease.